Evolus, Inc. (EOLS)

Over the past six months, Evolus's stock price has declined by 11.05%. Recent positive events include strong Q1 2026 financial results, with global net revenue of $73.1 million, a 7% increase over the prior year, and achieving its second consecutive quarter of positive Adjusted EBITDA. Following these results, EOLS shares traded up 4.69%. Evolus also ended its at-the-market (ATM) facility. However, BTIG and Mizuho revised their price targets downward.

Demand for Evolus, Inc. products and services exhibits seasonality, with the first quarter typically being a seasonally lower revenue quarter. Despite this, Evolus delivered strong Q1 2026 revenue. Evolus anticipates overcoming some unique dynamics from the prior year in Q2 2026, expecting high single-digit Jeuveau® growth in the first half of the year and supporting double-digit total revenue growth for the full year.

Evolus, Inc. is a performance beauty company in the Healthcare sector, focusing on innovative products in the cash-pay aesthetic market. Its major products include Jeuveau®, the fastest-growing neurotoxin in the U.S. for four years, and Evolysse™, a next-generation collection of injectable hyaluronic acid gels.

Evolus, Inc. has an expanding international footprint with operations in the United States, Canada, Europe, and Australia. In Europe, the company has a presence in countries such as Great Britain, Germany, Austria, Italy, Spain, Portugal, and Switzerland, with a direct operating entity established in Spain. The company's headquarters are located in Newport Beach, California, USA.

Evolus maintains a strong brand reputation, particularly with Jeuveau®, which has been the fastest-growing neurotoxin in the U.S. for four consecutive years. The Evolus Rewards consumer loyalty program is approaching 1.5 million members, with over 255,000 redemptions in Q1 2026. The reorder rate for its products is approximately 71%. The launch of Evolysse™ dermal fillers has also been a strategic win.

Evolus, Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Institutional ownership accounts for approximately 76.38% of the shares outstanding, while insider ownership is around 4.76%. Major institutional owners include Nantahala Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc.